Pipeline
Focused development in HBV-associated liver injury and chronic liver disease.
Curaem's lead PHF program is currently in preclinical-stage development, with a focus on standardized formulation, fingerprinting, validation data, and preparation for future clinical research.
Candidate · Indication
Discovery
Preclinical
Clinical
Regulatory / Commercial
Lead PHF Program
Standardized Plant-Derived Candidate
HBV-associated liver injuryFibrosisCirrhosisExploratory: NAFLD / NASH-related liver injury
Discovery
Complete
Preclinical
Current
Clinical
Planned
Regulatory / Commercial
Future
Pipeline status reflects internal development planning and is subject to regulatory, clinical, financing, and operational milestones.
Near-term development priorities
Where we're focused next.
01
Complete formulation standardization package
02
Finalize preclinical validation package
03
Prepare regulatory and clinical development pathway
04
Secure clinical-readiness funding
05
Build production and controlled cultivation capability
06
Establish future market access and strategic partnerships
Support the program